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Zusammenfassung
Hintergrund: Die Rolle der Leberchirurgie bei Leber -
metastasen gynäkologischer Tumoren ist bisher in der
 Literatur nicht geklärt. Aus diesem Grund haben wir
untersucht, inwieweit Patienten mit resektablen gegen -
über Patienten mit nichtresektablen Lebermetastasen
einen Überlebensvorteil haben. Patienten und Metho-
den: In die retrospektive Analyse wurden 43 Patienten
eingeschlossen, welche sich einer Operation bei Leber-
metastasen ausgehend von gynäkologischen Tumoren
unterzogen. Das Überleben der Patienten wurde anhand
der Kaplan-Meier-Methode ausgewertet und mittels Log-
Rank-Test miteinander verglichen. Ergebnisse: Die
 Patienten hatten als Primärtumor ein Mammakarzinom 
(n = 27), ein Ovarialkarzinom (n = 8) oder ein Uteruskarzi-
nom (n = 8). In 13 Fällen konnte keine Leberresektion vor-
genommen werden, und der Eingriff wurde als explorati-
ve Laparotomie beendet. Bei einer Mortalitätsrate von 0%
traten bei 18,7% kleinere Komplikationen auf. Das Ge-
samtüberleben aller Patienten mit möglicher Leberresek-
tion war signifikant größer (p < 0,05) als das der Patienten
mit nichtresektablen Lebermetastasen. Die weitere Sub-
gruppen-Analyse der Überlebensraten zeigte, dass insbe-
sondere Patienten mit Mammakarzinom ein signifikant
höheres (50%) 5-Jahresüberleben gegenüber den Patien-
ten mit einer Exploration aufwiesen. Schlussfolgerung:
Die Resektion von Lebermetastasen bei Patienten mit
 gynäkologischen Tumoren kann in selektierten Fällen mit
einem Überlebensvorteil ähnlich dem bei Patienten mit
Kolorektalkarzinommetastasen einhergehen. Daher sollte
den Patienten im Rahmen einer multidisziplinären Anti-
Tumortherapie eine Leberresektion in Kombination mit
einer Chemotherapie angeboten werden.
Key Words
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Summary
Background: Liver surgery for patients with liver metas-
tases from gynecological malignancies, an indicator of
advanced cancer disease, has remained unclear in the lit-
erature. We therefore analyzed the potential survival
benefit of patients with surgically resectable compared
to unresectable liver metastases. Patients and Meth-
ods: 43 patients who underwent surgery for liver metas-
tases from gynecological cancers were included in our
retrospective observational analysis. Overall survival
was estimated according to the Kaplan-Meier method
and compared with the log-rank test. Results: Primary
gynecological tumors were breast (n = 27), ovarian (n = 8),
and uterine (n = 8) cancers. Solely exploratory laparo -
tomy was performed in 13 patients who served as con-
trols. Whereas the perioperative mortality was 0%, minor
complications occurred in 18.7%. The overall survival of
all patients undergoing liver resection was significantly
higher (p < 0.05) than that of patients with unresectable
metastases. Subgroup analyses showed that particularly
patients with respectable liver metastases from breast
cancer had a significantly higher (50%) 5-year survival
compared to patients with only an exploratory laparo -
tomy. Conclusion: In selected patients, liver resection
of metastases from gynecological cancers can achieve a
survival benefit similar to that of patients with colorectal
cancer metastases.
Surgery of Liver Metastasis in Gynecological Cancer –
 Indication and Results
Otto Kollmar Mohammed R. Moussavian Sven Richter Martin Bolli Martin K. Schilling
Department of General, Visceral, Vascular and Pediatric Surgery, University of Saarland, Homburg/Saar, Germany
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 1
1:
59
:1
1 
AM
Introduction
Metastatic disease is the most common cause of death in pa-
tients with cancer [1]. Improved understanding of the hepatic
anatomy together with technical advances during the last
decades has enabled liver surgery to be performed with low
mortality rates and minimal morbidity [2, 3]. Furthermore,
modern surgical strategies from major hepatobiliary centers
have demonstrated that hepatectomy of as much as 70% of
the liver can be performed with a mortality rate of less than
5% [4, 5]. Until now, liver resection is the only curative treat-
ment option for patients with colorectal liver metastases and
intestinal endocrine tumors, as indicated by a 5-year survival
of up to 50% [6–8]. Additionally, anatomic resections reduce
the rate of positive tumor margins, and improve overall sur-
vival [9].
In contrast, in the literature, the role of liver resection for non-
colorectal and non-endocrine liver metastases is not well de-
fined. Historically, these patients with metastatic cancer would
be given supportive or palliative treatment including chemo -
therapy [10]. The rationale against hepatectomy of liver
metastases from non-colorectal and non-endocrine cancers is
the likelihood of disseminated disease, as the liver is usually
reached via the systemic circulation, and extrahepatic sites
may have equal probability of being involved (‘systemic dis-
ease’) [11]. Interestingly, a recent multicenter study by Adam
et al. [12] showed that liver resection for non-colorectal, non-
endocrine metastases is becoming more prevalent.
In gynecological malignancies, metastasis to the liver is an in-
dicator of advanced cancer disease [13]. In the literature, the
efficacy of liver surgery for patients with liver metastases from
gynecological cancers has remained unclear. Therefore, the
aim of the present study was to evaluate the potential survival
benefit of patients with surgically resectable compared to
 unresectable liver metastases.
Patients and Methods
Data from all patients were entered in a prospective database on an ISH-
Med SAP platform (SAP, St. Leon, Germany). Between January 2000 and
January 2007, 43 patients who underwent surgery for liver metastases
from gynecological cancers were enrolled in the study. All patients with
gynecological cancers had gynecological operations in combination with
or without chemotherapy and radiotherapy prior to surgery for their liver
metastases. All patients received antibiotic prophylaxis before surgery.
After abdominal exploration, resectability of the liver metastases was ver-
ified using intra-operative ultrasound of the liver. The criteria for non-
 resectability were infiltration of vessel and biliary structures in the hilus,
infiltration of all 3 liver veins, more than 10 liver metastases, and in-
traperitoneal metastasis. If liver resection was technically possible, partial
hepatectomy was performed as an anatomic or atypical resection under
Pringle maneuver or selective vascular clamping/occlusion. After liver
 resection, patients were transferred to the intensive care unit postopera-
tively. Data included all biographic and perioperative data as well as post-
operative outcome. Survival of the patients was assessed retrospectively in
November 2007.
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Data are expressed as absolute numbers or mean ± standard error of the
mean (SEM) unless indicated otherwise. The length of follow-up was cal-
culated from the date of liver resection at our institution. Overall survival
was estimated according to the Kaplan-Meier method and compared with
the log-rank test using the software package SPSS 14.0® (SPSS GmbH
Software, Munich, Germany).
Results
With respect to demographic data (table 1), the mean age of
the women was 55.7 ± 1.3 years at the time of liver surgery.
Primary tumor sites represented were breast (n = 27), ovarian
(n = 8), and uterine (n = 8) cancers. Pre- and postoperative
chemotherapy was used to treat primary tumors in 86% of
the patients. The mean time from gynecological treatment of
Table 1. Characteristics and preoperative treatment of all patients 
(n = 43) with gynecological cancer undergoing liver resection (Phx) at our
institution; mean ± standard error of the mean (SEM)
Age at the time of Phx, years 55.7 ± 1.3
ASA score 2.8 ± 0.2
Time between primary operation and Phx, months 76.9 ± 7.3
⎯⎯⎯⎯⎯⎯⎯
Patients, n
⎯⎯⎯⎯⎯⎯⎯
Primary tumor sites
Breast 27
Ovarian 8
Uterine 8
Pre-Phx chemotherapy/radiotherapy
Breast 27/16
Ovarian 7/0
Uterine 3/4
Table 2. Intra- and postoperative course of all patients (n = 43) who
underwent surgical procedures (n = 48) for liver metastases from gyneco-
logical cancer; mean ± standard error of the mean (SEM)
Operating time, min 153.6 ± 10.2
Blood loss, ml 325.7 ± 58.6
Postoperative hospital stay, days 9.4 ± 0.8
Postoperative stay on ICU, days 1.4 ± 0.2
Minor postoperative complications, patients, n 9
⎯⎯⎯⎯⎯⎯⎯
Procedures, n
⎯⎯⎯⎯⎯⎯⎯
Liver resection procedures (n = 30 patients) 35
Repeat hepatectomy for hepatic recurrence 
(n = 4 patients)  5
Exploratory laparotomy 13
Anatomic resection 20
Combined liver resection procedures (n = 11 patients) 12
Pringle maneuver 2
Selective vascular clamping or occlusion 10
Intraoperative transfusion (EC, FFP, TC units) 0
ICU = Intensive care unit; EC = erythrocyte concentrate; 
FFP = fresh frozen plasma; TC = thrombocyte concentrate.
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the primary tumor to liver resection was 76.9 ± 7.3 months.
No neoadjuvant chemo/radiotherapy for liver metastases was
performed. The 3 patients with synchronous liver metastases
received liver surgery within 4–6 weeks after the gynecolo -
gical operation for breast cancer. A total of 3 patients – 2 pa-
tients with breast cancer and 1 patient with ovarian cancer –
had synchronous liver metastases. All other patients had
metachronous disease. The distribution of the liver metas-
tases was uni- and/or bilobular. At the time of liver surgery,
only 1 patient with ovarian cancer metastases had extrahepat-
ic disease. The peritoneal metastases of this patient were re-
sected during the same operation. No liver resection could be
performed in 13 patients, and the operation was ended as an
exploratory laparotomy (table 2). Four patients with recur-
rent liver metastasis of breast cancer had a repeat hepatecto-
my, 1 patient even two repeat hepatectomies. Anatomic re-
sections based on the segments defined by Couinaud were
performed in 57% of patients. Major hepatectomy, defined as
resection of more than 2 anatomic segments, was required in
25% of the patients. Atypical and anatomic resections were
performed as single or combined procedures (n = 12 com-
bined multiple liver surgery procedures). Within 35 liver re-
section procedures performed in 30 patients, a total number
of 79 liver metastases were resected. The perioperative mor-
tality was 0%. Only minor complications occurred in 18.7%
of the 48 operations including e.g. urinary infection, pneumo-
nia, and cholangitis. The mean postoperative hospitalization
was 9.4 ± 0.8 days. Histologically, 3 patients with liver resec-
tions of metastases from breast cancer had an R1 resection
margin. One patient with breast cancer metastases was left
with an R2 situation after liver resection, and was treated
intra-operatively with cryotherapy of the resection margin.
All other patients with liver resection procedures (n = 31)
had an R0 resection margin. Patients with liver metastases
from ovarian cancer received adjuvant chemotherapy after
liver surgery.
After a mean follow-up interval of 29.4 ± 3.6 months, the over-
all 5-year survival for the entire cohort was 30% with a medi-
an overall survival of 51.8 months. The overall survival 
of patients undergoing liver resection was significantly higher 
(p = 0.002) than that of patients who received only an ex-
ploratory laparotomy (fig. 1). Patients with liver metastases
from primary breast tumors represented the largest subset in
our series (n = 27). Following hepatic resection, these patients
experienced 5-year survival of 50% which was significantly
higher (p = 0.018) compared to patients with only an ex-
ploratory laparotomy (median survival of 7.4 months (fig. 2)).
Subgroup analysis of patients with liver metastases from ovar-
ian and uterine cancers showed no significant differences be-
tween patients with resectable liver tumors and unresectable
liver tumors. Furthermore, analysis of all patients with liver
metastases from non-breast primary tumors showed longer
survival of patients with possible liver resection compared to
patients with exploratory laparotomy only, but these data did
not reach statistical significance (p = 0.063). In the case of in-
trahepatic recurrence, 4 of 27 patients with liver metastases
from breast cancer underwent a second hepatectomy, and one
of these 4 patients re-recurred in a resectable pattern, and un-
derwent a 3rd hepatectomy. Following repeated hepatectomy,
these 4 patients had a mean survival time of 52.9 months, com-
parable with a mean survival time of 57.1 months of patients
after a single hepatectomy.
Discussion
The major finding of the present study is that patients with
liver metastases from gynecological cancers have a survival
benefit whenever liver resection is possible, especially in cases
with breast cancer. In the present study, comparable to pre -
viously published data [2, 3], liver resection was safe for the pa-
tients, with no perioperative deaths and an acceptable minor
complication rate. Our study focused only on liver metastases
from gynecological cancers, which are not a common indica-
tion for liver resection. Because different primary tumor types
have different underlying tumor biology, the ideal study should
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Fig. 1. Overall sur-
vival of all patients
with liver metastases
from gynecological
cancers. Patients with
possible liver resec-
tion (black) had a sig-
nificantly (p < 0.05)
longer survival than
patients who under-
went an exploratory
laparotomy only
(white).
Fig. 2. Overall survival
of patients with liver
metastases from breast
cancer. Patients with
 potential liver resection
(black) were compared
with those who received
an exploratory laparoto-
my (white). Subgroup
analyses showed that
only patients with breast
cancer metastases had a
significantly longer sur-
vival after liver resec-
tion compared with con-
trols undergoing ex-
ploratory laparotomy.
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concentrate on only one tumor type. However, with regard to
the low number of patients, this is difficult [12, 14–19].
Liver surgery in breast cancer patients is viewed controver-
sially in the literature. On the rationale of oncologists, breast
cancer is a ‘systemic disease’. In contrast, as shown by Adam
et al. [11], liver resection provides a significant survival benefit
over medical therapy alone for patients with breast cancer
liver metastases. Analyzing their 108 patients with diagnosis
of hepatic metastases from breast cancer, the study group
identified response to preoperative chemotherapy, positive
 resection margin, and repeated hepatectomy for intrahepatic
recurrence as independent prognostic factors. According to
the reported overall 37% 5-year survival, we demonstrated in
the present study a similar overall 5-year survival of 50% for
patients with breast cancer alone.
Our data showed that aggressive intervention with liver re-
section for metastases from gynecological cancers was associ-
ated with a beneficial 50% 5-year survival after partial hepa-
tectomy. These findings are comparable to previous data by
Adam et al. [12], which demonstrated a 5-year survival rate
after resection of liver metastases from ovarian tumor sites of
50%, from breast cancer of 41%, and from uterine primaries
of 35%. Interestingly, our data showed a significant benefit
from liver resection compared to unresectable controls. Be-
cause our data represent a selection of patients undergoing
liver surgery and there is no randomized control group, this
uncertainty could lead to the hypothesis that the role of
 hepatic surgery for this group is cytoreduction only in chemo -
therapy-responsive tumors. As we know from the literature
[13], in ovarian cancer, surgical cytoreduction of intraperi-
toneal disease has a substantial effect on survival, whether
performed as a primary treatment, interval debulking, or sec-
ondary debulking for recurrent cancer. In this type of gyne -
cological cancer, survival of patients with partial hepatectomy
is similar to that of patients without liver disease but with
similar volumes of residual cancer [20–21]. In these cases,
only a longer disease-free interval remained a prognostic
 factor [13].
As shown in the present study, liver resection of metastases
from gynecological cancer can achieve a survival benefit simi-
lar to that of patients with colorectal cancer metastases. Taken
together, these findings could only be observed if each liver
metastasis of gynecological cancers could be removed. Addi-
tionally, previous studies in patients with non-colorectal
metastases showed that prognostic indicators for the survival
of these patients after partial hepatectomy are the type of liver
resection and complete tumor resection (R0) [12, 14–19].
 Furthermore, for the first time, our data did not demonstrate
any significant difference with respect to the type of gyneco-
logical cancer. This differs from the results of others [12,
14–19] who have identified primary tumor type as an impor-
tant prognostic factor. Unfortunately, no direct correlation to
our analysis is possible, because these studies include liver
metastases from all types of non-colorectal cancers.
In conclusion, with the very low mortality rate of liver resec-
tion, oncologists and surgeons should offer patients with liver
metastasis from gynecological cancer a multimodal multidisci-
plinary anti-cancer treatment approach including liver surgery
and chemotherapy.
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